BioSpace News Archive

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or “the Company”), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) (“Cosmo”), announced that it had successfully completed their Phase 2 Proof-of-Concept (POC) clinical trial of Rifamycin SV-MMX 600mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Fourth Quarter 2020 Revenue of Approximately $109.7 Million Full-Year 2020 Revenue of Approximately $362.0 Million Company to Present at J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 4:30 pm Eastern Time / 1:30 pm Pacific Time

Sosei Group Corporation, announced its Chief Financial Officer, Chris Cargill, will present at the 39th Annual J.P. Morgan Healthcare Conference, which will take place virtually, on Thursday, 14 January 2021.

Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells to treat cancers, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announce the signing of a clinical and commercial licensing agreement.

Second Genome, a leader in microbiome science, today announced that the company is presenting at the 13 th Annual Biotech Showcase Digital 2021 Conference this week. The conference is virtual and is occurring in parallel with the J.P. Morgan 39 th Annual Healthcare Conference 2021.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2021 milestones in conjunction with its presentation at the 39th Annual J.P. Morgan Virtual Healthcare Conference.

Blade Therapeutics today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference.

Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI).

Present Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Jan. 31 at World Conference on Lung Cancer

Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020